（一）本组简介

本组主要负责人为郑子峥副教授，课题组现有博士后3人，博士5人，硕士12人以及技术员2人。本组的主要研究对象是戊型肝炎病毒（HEV）及呼吸道合胞病毒（RSV），主要研究方向是通过研究病毒的感染及宿主免疫机制发现可以用于诊断、预防与治疗的靶点。

HEV研究方向主要从HEV衣壳蛋白关键domain入手，发现高亲和力表位、宿主结合表位及广谱中和表位，并将发现的靶点及其作用机制运用到高灵敏度诊断试剂的研发、病毒跨宿主传播机制以及疫苗作用机制的阐述中。基于本组的研究成果已成功开发出新一代HEV抗原高灵敏度诊断试剂，并确定该试剂在戊型肝炎的检测及确诊中起到重要作用。同时本组的研究还解释了HEV跨物种传播的潜在氨基酸变异及感染入胞的潜在途径，并发现了抗HEV抗体应答的潜在靶点。

RSV研究方向与美国国立卫生研究院下属疫苗研究中心（Vaccine Research Center，NIAID，NIH）在RSV领域展开合作，鉴定出了一株高效中和单抗能够稳固RSV融合蛋白F的瞬时构象，并发现了位于该构象上的强中和靶点，该表位已被成功运用到疫苗设计中，其系列研究成果作为疫苗领域的重要突破入选了Science杂志2013年度十大科技进展；同时该新发现抗体的体外中和活性比已上市的抗RSV抗体药物高50-100倍，具有很好的应用前景。最近，本组也筛选到了有望替代Synagis^® (Palivizumab)的新一代广谱高效中和抗体药物，目前正在积极开展临床前相关实验，展现了良好的临床转化潜能；同时本组研发的RSV灭活疫苗也正在进行临床前的验证阶段，有望成为未来新一代安全有效的RSV灭活疫苗；此外，本组成员也对RSV胞间传播机制阐述进行了深入的研究，提出了RSV胞间传播新假说，为RSV的防治提供了新的科学依据和理论指导。

（二）导师

郑子峥，Emial: zhengzizheng@xmu.edu.cn

（三）正在开展的项目

1. HEV致病机制研究

2. HEV新型刺刀抗体中和及诱导机制研究

3. HEV抗原诊断试剂在临床研究中应用价值

4. HEV受体研究

5. RSV疫苗研究

6. RSV 分子流行病学研究

7. RSV高中和抗体筛选及F蛋白高中和表位研究

8. 肿瘤浸润性B细胞研究

9. 预防/治疗SARS-CoV-2感染的人源抗体的工业化转化及感染恢复者抗体应答特征分析研究

（四）近5年来发表的部分文章

1. Dong Ying#, Qiyu He#, Weikun Tian#, et al. Urine is a viral antigen reservoir in hepatitis E virus infection. Hepatology,2022. (DOI: 10.1002/hep.32745)

2. Siling Wang, Hui Sun, Yali Zhang, et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Reports. 39(8):110862.

3. Hualong Xiong#, Hui Sun#, Siling Wang#, et al. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. PNAS,2022, 119(34):e2204256119.

4. Zi-Min Tang#, Gui-Ping# Wen, Dong Ying, et al. Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study. Emerging Microbes & Infections,2022,12(1):2140613.

5. Yong-Peng Sun, Si-Yu Lei, Ying-Bin Wang, et al. Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China. Microbiology Spectrum,2022, 10(2):e0208321.

6. Siling Wang#, Dinghui Wu#, Hualong Xiong#, et al. Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. Frontiers in Immunology,2022,13:952650.

7. Zihao Chen#, Junfeng Wei#, Li Jiang, et al, Zizheng Zheng*, Li Yan* and Ningshao Xia*. Chronic hepatitis E in a hematopoietic stem cell transplant recipient: The first report of hepatitis E virus genotype 4 causing chronic infection in a non-solid organ recipient. Frontiers in Immunology,2022, 13:954697.

8. Xin Wang , Xiaochen Yin , Boya Zhang, Chenfeng Liu, Yahua Lin, Xiaofen Huang, Yufang Li, Chenguang Shen, Weibin Zheng, Guofeng Fu, Junyu Chen , Yanling Wen , Wei Zhang , Bo-Sheng Pan, Mujin Fang, Zizheng Zheng, Zheng Zhang , et al. A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. Emerging Microbes & Infections,2022, 11(1):914-925.

9. Zihao Chen#, Shaoqi Guo#, Guanghui Li, et al. A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity. Viruses,2022, 14(10):2122.

10. Min Lin#, Wei Zhang#, Yi-Fan Yin#, et al. An optimized FI-RSV vaccine effectively protects cotton rats and BALB/c mice without causing enhanced respiratory disease. Viruses,2022, 14(10):2085.

11. Li Ping Wong，Haridah Alias，Seow Huey Choy，Xiang Ting Goh，Soo Ching Lee，Yvonne Ai Lian Lim，Boon Pin Kee，Kek Heng Chua，Adeeba Kamaruzaman，Zizheng Zheng，et al. The study of seroprevalence of hepatitis E virus and an investigation into the lifestyle behaviours of the aborigines in Malaysia. Zoonoses and Public Health,2020, 67(3):263-270.

12. Siling Wang #, Yangling Wu#, Yizhen Wang#, et al. Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection. Journal of Virological Methods,2022, 309:114597.

13. Li Ping Wong , Hai Yen Lee , Chee Sieng Khor, Juraina Abdul-Jamil, Haridah Alias, Noryati Abu-Amin, Murniwati Mat-Radzi, Nurul Ashila Rohimi, Hana Najian Mokhtardin , Sazaly AbuBakar, Zizheng Zheng, Ting Wu. The Risk of Transfusion-Transmitted Hepatitis E Virus: Evidence from Seroprevalence Screening of Blood Donations. Indian J Hematol Blood Transfus,2022,38(1):145-152.

14. Yong-Peng Sun#. Xin-Yi Zheng# . Hai-Xia Zhang . et al. Epidemiology of Respiratory Pathogens Among Children Hospitalized for Pneumonia in Xiamen: A Retrospective Study. Infectious Diseases and Therapy,2021,10(3):1567-1578.

15. Lihui Wei, Yingying Su, Yuemei Hu, Rongcheng Li, Wen Chen, Qinjing Pan, Xun Zhang, Fanghui Zhao, Yuqian Zhao, Qing Li, Ying Hong, Chao Zhao, Mingqiang Li,  Wenyu Liu, Caihong Li, Dongping Guo, Lidong Ke, Bizhen Lin, Zhijie Lin, Shu Chen, Wei Sheng, Zizheng Zheng, et al. Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial. Clinical Microbiology and Infection,2020,26(8):1069-1075.

16. Gui-Ping Wen, Linling He, Zi-Min Tang, et al. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications,2020,11(1):3971.

17. Su YY, Lin BZ, Zhao H, Li J, Lin ZJ, Qiao YL, Wei LH, Hu YM, Li RC, Zhuang SJ, Sun G, Zheng ZZ, et al. Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial. Human Vaccines & Immunotherapeutics,2020,16(7):1636-1644.

18. Liu C, Cai W, Yin X, et al. An optimized high-throughput neutralization assay for hepatitis E virus (HEV) involving detection of secreted pORF2. Viruses,2019,11(1):64.

19. Wei Zhang#, Lujing Zhang#, Luting Zhan, et al. The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein. Viruses,2019,11(7):628.

20. Qingbing Zheng, Jie Jiang, Maozhou He, Zizheng Zheng, et al. Viral neutralization by antibody-imposed physical disruption.PNAS,2019,116(52):26933-26940.

21. Kaihang Wang, Lizhi Zhou, Xiao Zhang, Cuiling Song, Tingting Chen, Jiajia Li, Minghua Zheng, Yinbin Wang, Qingbing Zheng, Zizheng Zheng, et al. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Research,2019,164:154-161.

22. Liu X, Liu C, Zheng Z, et al. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Advanced Materials,2019,31(17):e1808294.

23. Xin Yin, Dong Ying, Sébastien Lhomme, Zimin Tang, Christopher M. Walker, Ningshao Xia, Zizheng Zhengb,and Zongdi Feng. Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. PNAS,2018,115(8):4773-4778.

24. Chenguang Shen#, Junyu Chen#, Rui Li#, Mengya Zhang#, Guosong Wang#, Jing Chen, Jianli Cao, Limin Zhang, Xingjian Bi, Hai Yu, Kunyu Yang, Stephen F. Anderson, Timothy Alefantis, Shaojun Ke, Yanbin Wu, Qiangyuan Han, Qingbing Zheng, Mujing Fang, Wenxin Luo, Zizheng Zheng, Quan Yuan, Jun Zhang, J. Wai-Kuo Shih, Harold Kleanthous, Honglin Chen, Yixin Chen*, Ningshao Xia*. A novel multimechanistic antibody targeting receptor-binding sites potently cross-protects against influenza B viruses since 1940. Sci Transl Med. 2017, 18;9(412).

25. Daiyin Tian#，Michael B. Battles#, Syed M. Moin, Man Chen， Kayvon Modjarrad, Azad Kumar,Masaru Kanekiyo, Kevin W. Graepel, Noor M. Taher, Anne L. Hotard, Martin L. Moore, Min Zhao,Zi-Zheng Zheng,,Ning-Shao Xia*, Jason S. McLellan*& Barney S. Graham*. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017; 8: 1877.

26. Gui-Ping Wen, Zi-Min Tang, Si-Ling Wang, et al. Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection. Appl Microbiol Biotechnol. 2017;101(23-24):8585-8594.

（五）招生要求